Companies Directory

Amphion Loudspeakers Ltd. has been designing and building loudspeakers in Finland since 1998. Our studio monitors and home loudspeakers are characterised by highly resolving and natural reproduction. Precise driver integration ensures world-class imaging and phase coherence. Controlled dispersion helps achieving more stable results in variety of room acoustics. All products are handmade in Finland to ensure enduring listening quality.

Amphiro AG is a Cleantech-Spinoff from ETH Zurich under the ownership of its founders. Amphiro is supported by the Commission for Technology and Innovation (CTI), the Swiss Federal Office for the Environment (BAFU), and ETH Transfer. Amphiro was founded in 2009 by doctoral candidates of ETH Zurich. From the first day, the team pursued the goal to increase comfort and energy efficiency of one of the most widely used products in the world: faucets. Our mission: By the year 2020, more than 10% of all faucets sold will be equipped with Amphiro technology.

We help you 1) Create better analytics for your customers 2) Integrate across the ecosystem and reduce development effort 3) Increase revenue through better products and more customers 4) Focus on building great hardware rather than data engineering and wrangling 5) Manage privacy and only allow specific companies to use the data, e.g. only partners not competitors.

Amphora is one of the world's leading suppliers of replacements for the Bound Laboratory Notebook. Our solutions are in use around the world by companies large and small, helping scientists work better, collaborate easily with each other, and protect their inventions.

Our mission is rapid development of antimicrobial peptides (AMPs) as alternatives to conventional small molecule antibiotics. As a Research and Development Biotechnology Company we are generating solutions against antimicrobial resistance, safeguarding human health and securing the food chain for a growing world population. Our current target is to translate AMPs for use in veterinary applications – specifically in poultry meat and egg production. Our long-term vision is to develop novel human therapeutics. Antimicrobial drugs based on small molecule antibiotic compounds have saved countless lives since the discovery of penicillin in 1928. However, these drugs have now lost or are losing effectiveness as microbes become resistant. Antimicrobial resistance threatens to kill 10 million people a year by 2050, and to slow or even reverse modern medical advances in surgery, organ transplantation, and cancer treatment. Antibiotics were routinely used in North American farms until recently, to keep animals healthy and protect human health by preventing food-borne illness outbreaks. The practice also had a positive effect on animal growth. In response to antimicrobial resistance, regulators in the US (2017) and Canada (2018) have restricted veterinary use of all medically important antimicrobials to prescription-only applications. These necessary changes have created an economic burden for farmers, who are looking for antibiotic replacements. Antimicrobial peptides are one potential alternative to conventional small molecule antibiotics. AMPs act faster than small molecule antimicrobials, and do not cause DNA damage. As a result, they do not induce resistance to the same degree as conventional antibiotics. Further, AMPs used in the agricultural sector would be broken down in farm animals' bodies and would not persist in the meat or eggs, nor in agricultural waste products.